Expert opinion on drug delivery最新文献_第9页

The quest to deliver high-dose rifampicin: can the inhaled approach help? 寻求提供大剂量利福平：吸入式方法是否有用？

Expert opinion on drug delivery Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI: 10.1080/17425247.2024.2301931

Prakash Khadka, Jack Dummer, Philip C Hill, Shyamal C Das

{"title":"The quest to deliver high-dose rifampicin: can the inhaled approach help?","authors":"Prakash Khadka, Jack Dummer, Philip C Hill, Shyamal C Das","doi":"10.1080/17425247.2024.2301931","DOIUrl":"10.1080/17425247.2024.2301931","url":null,"abstract":"Introduction: Tuberculosis (TB) is a global health problem that poses a challenge to global treatment programs. Rifampicin is a potent and highly effective drug for TB treatment; however, higher oral doses than the standard dose (10 mg/kg/day) rifampicin may offer better efficacy in TB treatment.Areas covered: High oral dose rifampicin is not implemented in anti-TB regimens yet and requires about a 3-fold increase in dose for increased efficacy. We discuss inhaled delivery of rifampicin as an alternative or adjunct to oral high-dose rifampicin. Clinical results of safety, tolerability, and patient compliance with antibiotic dry powder inhalers are reviewed.Expert opinion: Clinical trials suggest that an approximately 3-fold increase in the standard oral dose of rifampicin may be required for better clinical outcomes. On the other hand, animal studies suggest that inhaled rifampicin can deliver a high concentration of the drug to the lungs and achieve approximately double the plasma concentration than that from oral rifampicin. Clinical trials on inhaled antibiotics suggest that dry powder inhalation is a patient-friendly and well-tolerated approach in treating respiratory infections compared to conventional treatments. Rifampicin, a well-known anti-TB drug given orally, is a good candidate for clinical development as a dry powder inhaler.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139099422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Engineered exosomes derived from stem cells: a new brain-targeted strategy. 源自干细胞的工程外泌体：一种新的脑靶向策略。

Expert opinion on drug delivery Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI: 10.1080/17425247.2024.2306877

Waqas Ahmed, Songze Huang, Lukui Chen

{"title":"Engineered exosomes derived from stem cells: a new brain-targeted strategy.","authors":"Waqas Ahmed, Songze Huang, Lukui Chen","doi":"10.1080/17425247.2024.2306877","DOIUrl":"10.1080/17425247.2024.2306877","url":null,"abstract":"Introduction: Using engineered exosomes produced from stem cells is an experimental therapeutic approach for treating brain diseases. According to reports, preclinical research has demonstrated notable neurogenesis and angiogenesis effects using modified stem cell-derived exosomes. These biological nanoparticles have a variety of anti-apoptotic, anti-inflammatory, and antioxidant properties that make them very promising for treating nervous system disorders.Areas covered: This review examines different ways to enhance the delivery of modified stem cell-derived exosomes, how they infiltrate the blood-brain barrier (BBB), and how they facilitate their access to the brain. We would also like to determine whether these nanoparticles have the most significant transmission rates through BBB when targeting brain lesions.Expert opinion: Using engineered stem cell-derived exosomes for treating brain disorders has generated considerable attention toward clinical research and application. However, stem cell-derived exosomes lack consistency, and their mechanisms of action are uncertain. Therefore, upcoming research needs to prioritize examining the underlying mechanisms and strategies via which these nanoparticles combat neurological disorders.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139522421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intramuscular injection of palmitic acid-conjugated Exendin-4 loaded multivesicular liposomes for long-acting and improving in-situ stability. 肌内注射棕榈酸结合的外显子素-4负载多囊脂质体，可实现长效并提高原位稳定性。

Expert opinion on drug delivery Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI: 10.1080/17425247.2024.2305110

Huixian Tian, Minsi Chang, Yanlin Lyu, Nan Dong, Nini Yu, Tian Yin, Yu Zhang, Haibing He, Jingxin Gou, Xing Tang

{"title":"Intramuscular injection of palmitic acid-conjugated Exendin-4 loaded multivesicular liposomes for long-acting and improving in-situ stability.","authors":"Huixian Tian, Minsi Chang, Yanlin Lyu, Nan Dong, Nini Yu, Tian Yin, Yu Zhang, Haibing He, Jingxin Gou, Xing Tang","doi":"10.1080/17425247.2024.2305110","DOIUrl":"10.1080/17425247.2024.2305110","url":null,"abstract":"Background: Exendin-4 (Ex4) is a promising drug for diabetes mellitus with a half-life of 2.4 h in human bodies. Besides, the Ex4 formulations currently employed in the clinic or under development have problems pertaining to stability. In this study, palmitic acid-modified Ex4 (Pal-Ex4) was prepared and purified to extend the half-life of Ex4. In addition, Pal-Ex4-MVLs were further designed and optimized as a long-acting delivery system for intramuscular injection.Methods: Pal-Ex4 was encapsulated within multivesicular liposomes (MVLs) via a two-step double emulsification process. The formulated products were then assessed for their vesicle size, encapsulation efficiency, and in vitro and in vivo.Results: Pal-Ex4-MVLs with a notable encapsulation efficiency of 99.18% were successfully prepared. Pal-Ex4-MVLs, administered via a single intramuscular injection in Sprague-Dawley rats, sustained stable plasma concentrations for 168 h, presenting extended half-life (77.28 ± 12.919 h) and enhanced relative bioavailability (664.18%). MVLs protected Ex4 through providing stable retention and slow release. This approach considerably improved the in-situ stability of the drug for intramuscular administration.Conclusions: The combination of palmitic acid modification process with MVLs provides dual protection for Ex4 and can be a promising strategy for other hydrophilic protein/polypeptide-loaded sustained-release delivery systems with high drug bioactivity.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139467576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lipidated brush-PEG polymers as low molecular weight pulmonary drug delivery platforms. 作为低分子量肺部给药平台的脂质刷状聚乙二醇聚合物。

Expert opinion on drug delivery Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI: 10.1080/17425247.2024.2305116

Lisa M Kaminskas, Neville J Butcher, Christopher N Subasic, Ashok Kothapalli, Shadabul Haque, James L Grace, Alexander Morsdorf, Joanne T Blanchfield, Andrew K Whittaker, John F Quinn, Michael R Whittaker

{"title":"Lipidated brush-PEG polymers as low molecular weight pulmonary drug delivery platforms.","authors":"Lisa M Kaminskas, Neville J Butcher, Christopher N Subasic, Ashok Kothapalli, Shadabul Haque, James L Grace, Alexander Morsdorf, Joanne T Blanchfield, Andrew K Whittaker, John F Quinn, Michael R Whittaker","doi":"10.1080/17425247.2024.2305116","DOIUrl":"10.1080/17425247.2024.2305116","url":null,"abstract":"Objectives: Nanomedicines are being actively developed as inhalable drug delivery systems. However, there is a distinct utility in developing smaller polymeric systems that can bind albumin in the lungs. We therefore examined the pulmonary pharmacokinetic behavior of a series of lipidated brush-PEG (5 kDa) polymers conjugated to 1C2, 1C12 lipid or 2C12 lipids.Methods: The pulmonary pharmacokinetics, patterns of lung clearance and safety of polymers were examined in rats. Permeability through monolayers of primary human alveolar epithelia, small airway epithelia and lung microvascular endothelium were also investigated, along with lung mucus penetration and cell uptake.Results: Polymers showed similar pulmonary pharmacokinetic behavior and patterns of lung clearance, irrespective of lipid molecular weight and albumin binding capacity, with up to 30% of the dose absorbed from the lungs over 24 h. 1C12-PEG showed the greatest safety in the lungs. Based on its larger size, 2C12-PEG also showed the lowest mucus and cell membrane permeability of the three polymers. While albumin had no significant effect on membrane transport, the cell uptake of C12-conjugated PEGs were increased in alveolar epithelial cells.Conclusion: Lipidated brush-PEG polymers composed of 1C12 lipid may provide a useful and novel alternative to large nanomaterials as inhalable drug delivery systems.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139514087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progress and challenges in intravesical drug delivery. 膀胱内给药的进展与挑战。

Expert opinion on drug delivery Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI: 10.1080/17425247.2024.2307481

Arpita Banerjee, Dongtak Lee, Christopher Jiang, Rong Wang, Zoe Bogusia Kutulakos, Sohyung Lee, Jingjing Gao, Nitin Joshi

{"title":"Progress and challenges in intravesical drug delivery.","authors":"Arpita Banerjee, Dongtak Lee, Christopher Jiang, Rong Wang, Zoe Bogusia Kutulakos, Sohyung Lee, Jingjing Gao, Nitin Joshi","doi":"10.1080/17425247.2024.2307481","DOIUrl":"10.1080/17425247.2024.2307481","url":null,"abstract":"Introduction: Intravesical drug delivery (IDD) has gained recognition as a viable approach for treating bladder-related diseases over the years. However, it comes with its set of challenges, including voiding difficulties and limitations in mucosal and epithelial penetration. These challenges lead to drug dilution and clearance, resulting in poor efficacy. Various strategies for drug delivery have been devised to overcome these issues, all aimed at optimizing drug delivery. Nevertheless, there has been minimal translation to clinical settings.Areas covered: This review provides a detailed description of IDD, including its history, advantages, and challenges. It also explores the physical barriers encountered in IDD, such as voiding, mucosal penetration, and epithelial penetration, and discusses current strategies for overcoming these challenges. Additionally, it offers a comprehensive roadmap for advancing IDD into clinical trials.Expert opinion: Physical bladder barriers and limitations of conventional treatments result in unsatisfactory efficacy against bladder diseases. Nevertheless, substantial recent efforts in this field have led to significant progress in overcoming these challenges and have raised important attributes for an optimal IDD system. However, there is still a lack of well-defined steps in the workflow to optimize the IDD system for clinical settings, and further research is required to establish more comprehensive in vitro and in vivo models to expedite clinical translation.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139486409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Solubility-enabling formulations for oral delivery of lipophilic drugs: considering the solubility-permeability interplay for accelerated formulation development. 用于口服给药的亲脂性药物溶解度赋能配方：考虑溶解度与渗透性之间的相互作用以加速配方开发。

Expert opinion on drug delivery Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI: 10.1080/17425247.2023.2298247

Noa Fine-Shamir, Arik Dahan

{"title":"Solubility-enabling formulations for oral delivery of lipophilic drugs: considering the solubility-permeability interplay for accelerated formulation development.","authors":"Noa Fine-Shamir, Arik Dahan","doi":"10.1080/17425247.2023.2298247","DOIUrl":"10.1080/17425247.2023.2298247","url":null,"abstract":"Introduction: Tackling low water solubility of drug candidates is a major challenge in today's pharmaceutics/biopharmaceutics, especially by means of modern solubility-enabling formulations. However, drug absorption from these formulations oftentimes remains unchanged or even decreases, despite substantial solubility enhancement.Areas covered: In this article, we overview the simultaneous effects of the formulation on the solubility and the apparent permeability of the drug, and analyze the contribution of this solubility-permeability interplay to the success/failure of the formulation to increase the overall absorption and bioavailability. Three different patterns of interplay were identified: (1) solubility-permeability tradeoff in which every solubility gain comes with a price of concomitant permeability loss; (2) an advantageous interplay pattern in which the permeability remains unchanged alongside the solubility gain; and (3) an optimal interplay pattern in which the formulation increases both the solubility and the permeability. Passive vs. active intestinal permeability considerations in the context of the solubility-permeability interplay are also thoroughly discussed.Expert opinion: The solubility-permeability interplay pattern of a given formulation has a critical effect on its overall success/failure, and hence, taking into account both parameters in solubility-enabling formulation development is prudent and highly recommended.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A review on the use of extracellular vesicles for the delivery of drugs and biological therapeutics. 细胞外囊泡用于药物和生物治疗的综述。

Expert opinion on drug delivery Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI: 10.1080/17425247.2024.2305115

Sundus Jabeen Amina, Tasmia Azam, Fatima Dagher, Bin Guo

{"title":"A review on the use of extracellular vesicles for the delivery of drugs and biological therapeutics.","authors":"Sundus Jabeen Amina, Tasmia Azam, Fatima Dagher, Bin Guo","doi":"10.1080/17425247.2024.2305115","DOIUrl":"10.1080/17425247.2024.2305115","url":null,"abstract":"Introduction: Exosomes, a type of extracellular vesicles, are effective tools for delivering small-molecule drugs and biological therapeutics into cells and tissues. Surface modifications with targeting ligands ensure precise delivery to specific cells, minimizing accumulation in healthy organs and reducing the side effects. This is a rapidly growing area in drug delivery research and this review aims to comprehensively discuss the recent advances in the field.Area covered: Recent studies have presented compelling evidence supporting the application of exosomes as efficient delivery vehicles that escape endosome trapping, achieving effective in vivo delivery in animal models. This review provides a systemic discussion on the exosome-based delivery technology, with topics covering exosome purification, surface modification, and targeted delivery of various cargos ranging from siRNAs, miRNAs, and proteins, to small molecule drugs.Expert opinion: Exosome-based gene and drug delivery has low toxicity and low immunogenicity. Surface modifications of the exosomes can effectively avoid endosome trapping and increase delivery efficiency. This exciting technology can be applied to improve the treatments for a wide variety of diseases.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139472732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polypeptides as alternatives to PEGylation of therapeutic agents. 多肽作为治疗剂 PEG 化的替代品。

Expert opinion on drug delivery Pub Date : 2023-12-20 DOI: 10.1080/17425247.2023.2297937

Huali Chen, Qianyu Zhang

{"title":"Polypeptides as alternatives to PEGylation of therapeutic agents.","authors":"Huali Chen, Qianyu Zhang","doi":"10.1080/17425247.2023.2297937","DOIUrl":"https://doi.org/10.1080/17425247.2023.2297937","url":null,"abstract":"Introduction: Due to the concerns raised by the extensive application of PEGylation, polypeptides have stood out as excellent candidates with adequate biocompatibility and biodegradability with tunable hydrophilicity.Areas covered: In this review, polypeptides with the potential to replace PEGylation have been summarized and their application has been reviewed, including XTEN, PASylation, polysarcosine, zwitterion polypeptides, ELPylation, etc. Besides their strengths, the remaining challenges have also been discussed and the future perspectives have been provided.Expert opinion: Polypeptides have been applied in the designing of peptide/protein drugs as well as nanomedicines, and some of the pharmaceutics have made it into the clinical trials and got approved. These polypeptides showed similar hydrophilic properties to PEGylation, which increased the hydrodynamic volumes of protein drugs, reduced kidney elimination, decreased protein-polymer interaction and potentially improved the drug delivery efficiency due to the extended circulation time in the system. Moreover, they demonstrated superior biodegradability and biocompatibility, compensating for the deficiencies for polymers such as PEG.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inhalation delivery of nucleic acid gene therapies in preclinical drug development. 核酸基因疗法在临床前药物开发中的吸入递送。

Expert opinion on drug delivery Pub Date : 2023-07-01 Epub Date: 2023-10-16 DOI: 10.1080/17425247.2023.2261369

Conor A Ruzycki, Derek Montoya, Hammad Irshad, Jason Cox, Yue Zhou, Jacob D McDonald, Philip J Kuehl

{"title":"Inhalation delivery of nucleic acid gene therapies in preclinical drug development.","authors":"Conor A Ruzycki, Derek Montoya, Hammad Irshad, Jason Cox, Yue Zhou, Jacob D McDonald, Philip J Kuehl","doi":"10.1080/17425247.2023.2261369","DOIUrl":"10.1080/17425247.2023.2261369","url":null,"abstract":"Introduction: Inhaled gene therapy programs targeting diseases of the lung have seen increasing interest in recent years, though as of yet no product has successfully entered the market. Preclinical research to support such programs is critically important in maximizing the chances of developing successful candidates.Areas covered: Aspects of inhalation delivery of gene therapies are reviewed, with a focus on preclinical research in animal models. Various barriers to inhalation delivery of gene therapies are discussed, including aerosolization stresses, aerosol behavior in the respiratory tract, and disposition processes post-deposition. Important aspects of animal models are considered, including determinations of biologically relevant determinations of dose and issues related to translatability.Expert opinion: Development of clinically-efficacious inhaled gene therapies has proven difficult owing to numerous challenges. Fit-for-purpose experimental and analytical methods are necessary for determinations of biologically relevant doses in preclinical animal models. Further developments in disease-specific animal models may aid in improving the translatability of results in future work, and we expect to see accelerated interests in inhalation gene therapies for various diseases. Sponsors, researchers, and regulators are encouraged to engage in early and frequent discussion regarding candidate therapies, and additional dissemination of preclinical methodologies would be of immense value in avoiding common pitfalls.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41150848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current status of porous coordination networks (PCNs) derived porphyrin spacers for cancer therapy. 用于癌症治疗的多孔配位网络（PCNs）衍生的卟啉间隔物的现状。

Expert opinion on drug delivery Pub Date : 2023-07-01 Epub Date: 2023-10-17 DOI: 10.1080/17425247.2023.2260309

Jeifeng Huang, Donghui Liao, Yuting Han, Ying Chen, Saleem Raza, Chengyu Lu, Jianqiang Liu, Qian Lan

{"title":"Current status of porous coordination networks (PCNs) derived porphyrin spacers for cancer therapy.","authors":"Jeifeng Huang, Donghui Liao, Yuting Han, Ying Chen, Saleem Raza, Chengyu Lu, Jianqiang Liu, Qian Lan","doi":"10.1080/17425247.2023.2260309","DOIUrl":"10.1080/17425247.2023.2260309","url":null,"abstract":"Introduction: Porous coordination networks (PCNs) have been widely used in large number of applications such as light harvesting, catalysis, and biomedical applications. Inserting porphyrins into PCNs scaffolds can alleviate the solubility and chemical stability problems associated with porphyrin ligands and add functionality to PCNs. The discovery that some PCNs materials have photosensitizer and acoustic sensitizer properties has attracted significant attention in the field of biomedicine, particularly in cancer therapy. This article describes the latest applications of the porphyrin ligand-based family of PCNs in cancer chemodynamic therapy (CDT), photodynamic therapy (PDT), sonodynamic therapy (SDT), photothermal therapy (PTT), and combination therapies and offers some observations and reflections on them.Areas covered: This article discusses the use of the PCN family of MOFs in cancer treatment, specifically focusing on chemodynamic therapy, sonodynamic therapy, photodynamic therapy, photothermal therapy, and combination therapy.Expert opinion: Although a large number of PCNs have been developed for use in novel cancer therapeutic approaches, further improvements are needed to advance the use of PCNs in the clinic. For example, the main mechanism of action of PCNs against cancer and the metabolic processes in organisms, and how to construct PCNs that maintain good stability in the complex environment of organisms.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41158274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1